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The distribution of neuromedin N and its structurally related peptide, neurotensin, was investigated in the 
rat and found to be remarkably similar with highest concentrations in the ileum. However, neuromedin N 
but not neurotensin was found in the kidney. Chromatographic analysis of immunoreactive neuromedin 
N demonstrated asingle peak of immunoreactivity which was distinguishable from the single peak of immu- 
noreactive neurotensin. Neuromedin N is likely to be a naturally occurring peptide and is distinct from neu- 
rotensin in rat peripheral tissues. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Neuromedin N, a six amino acid peptide, was 
recently isolated and purified from porcine spinal 
cord [I]. It has close sequence homology with 
neurotensin, a thirteen amino acid peptide widely 
distributed in the central nervous system and 
gastrointestinal tract of numerous mammalian 
species [2,3]. Neuromedin N enhances the contrac- 
tility of guinea pig ileum [l], and has recently been 
reported to mimic the biological action of neuro- 
tensin in the rat ventral tegmental area [4]. The 
distribution of neuromedin N is unknown at pres- 
ent and because of its structural homology with 
neurotensin, we have investigated and compared 
the distribution of immunoreactive neuromedin N 
with that of neurotensin. Immunoreactive neuro- 
medin N has been analysed by gel filtration and 
reverse high-pressure liquid chromatography 
(HPLC). 
2.1. Immunisation and iodination 
Neuromedin N (Peninsula Lab) was coupled to 
bovine serum albumin in a molar ratio of 4: 1 by 
the glutaraldehyde method. Six rabbits received 
100 nmol neuromedin N initially. Booster injec- 
tions of 50 nmol conjugated neuromedin N were 
given at 5-8 weekly intervals. 1251-neuromedin N 
was prepared by the chloramine T method [5]. The 
iodination product was purified by HPLC using a 
Techsil Cl8 column eluted with a stepwise gradient 
of acetonitrile from 20 to 80% containing 0.1% 
aqueous trifluoroacetic acid. 
2.2. Tissue extraction and radioimmunoassay 
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Adult Wistar rats were killed by decapitation. 
Tissues were dissected, weighed, and extracted im- 
mediately in boiling 0.5 M acetic acid for 10 min 
(10: 1, v/w). Tissue extracts were centrifuged for 
15 min at 4”C, and supernatants were lyophilised. 
The samples were reconstituted in assay buffer 
(0.06 M phosphate buffer, pH 7.4, 10 mM EDTA, 
0.3% gelatin). Aliquots were taken for assays for 
neuromedin N and neurotensin. 
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Radioimmunoassays were set up in polystyrene 
tubes in a final volume of 0.8 ml with assay buffer. 
The final titre of the neuromedin N antiserum used 
was 1:4000, and the sensitivity of the assay was 
75 fmol/tube. Measurements of immunoreactive 
neurotensin were as previously described [6], with 
both the C-terminally directed antiserum (NT58), 
and an N-terminally directed antiserum (a gift 
from Dr T. Moody). 
2.3. Chromatographic analysis 
Tissue extracts were pooled, and semi-purified 
on Sep-pak Cl8 sample preparation cartridges 
(Waters Associates, USA) prior to chromatogra- 
phy. Gel filtration and HPLC were performed as 
in [6]. For gel filtration, fractions of 2.0 ml were 
collected and evaporated to dryness. The fractions 
were reconstituted in 0.7 ml assay buffer, 0.6 ml 
of each fraction was assayed for neuromedin N, 
and 0.5 ml of each fraction was assayed for neuro- 
tensin with the C-terminally directed antiserum. 
For HPLC, fractions of 1 ml were collected and 
100~1 of each fraction was assayed for neuro- 
medin N, and neurotensin with both the C- and N- 
terminally directed antisera. 
3. RESULTS AND DISCUSSION 
This study demonstrates the discrete localization 
Table 1 
Regional distribution of immunoreactive neuromedin N 
and neurotensin in the rat (pmol peptide/g wet wt, mean 
+ SE, n = 8) 
Region NNLI NTLP NTLIb 
Stomach 1.0 f 0.6 <0.4 <0.6 
Jejunum 2.8 f 1.5 5.7 k 0.9 5.3 k 0.8 
Ileum 40.8 t- 5.9 89.6 + 6.4 94.1 t 8.6 
Caecum 7.0 f 1.4 15.5 + 1.9 26.3 k 3.6 
Asc. colon 4.5 + 2.1 15.3 f 2.2 9.9 k 2.7 
Trans. colon <0.8 1.9 k 0.6 1.6 k 1.2 
Desc. colon <0.8 <0.4 <0.6 
Liver 3.3 -t 1.1 <0.4 <0.6 
Kidney 17.0 k 0.6 <0.4 <0.6 
Heart 6.1 k 1.6 <0.4 <0.6 
Lung 3.3 + 1.3 <0.4 <0.6 
a lmmunoreactive neurotensin measured with C- 
terminal antiserum 
b Immunoreactive neurotensin measured with N- 
terminal antiserum 
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of neuromedin N in the peripheral tissues of the rat 
by radioimmunoassay. The cross-reactivity of 
neuromedin N antiserum with neurotensin 1-13 
was 4.2% and with neurotensin 7-13, 9-13, lo-13 
(gifts from Dr St Pierre) and lant-6, 6.6%. There 
was no cross-reactivity with tufsin, neuromedin B, 
C, and U, or other regulatory peptides including 
substance P, neurokinins, peptide YY, neuropep- 
tide Y, cholecystokinin, or gastrin. Table 1 shows 
the distribution of neuromedin N, and neurotensin 
as measured using both the C- and N-terminally 
directed antisera. The highest concentrations of 
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Fig.1. Gel filtration profiles of neuromedin N (NNLI) 
(upper) and neurotensin (NTLI) (lower) of pooled rat il- 
eal extracts. The Sephadex G-50 superfine column 
(1.5 x 90 cm) was eluted with 0.06 M phosphate buffer, 
pH 7.4, containing 0.3% BSA and 0.2 M sodium chlo- 
ride at 4°C. The elution positions of void volume ( VO) 
and total volume (Vl), synthetic neuromedin N and 
neurotensin are indicated. 
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neuromedin N, 40.8 f 5.9 pmol/g (mean f SE), 
were found in the terminal ileum. Considerable 
amounts were also found in the rat whole kidney, 
17.0 + 0.6 pmol/g (mean + SE). Neurotensin had 
a similar pattern of distribution in the gut. How- 
ever, 2-3-fold higher concentrations of neuro- 
tensin were detected in the same tissue extracts. 
Chromatographic characterization with both gel 
filtration and HPLC of the rat ileum and kidney 
extracts demonstrated that immunoreactivity co- 
eluted with synthetic neuromedin N (figs 1,2). 
When the same chromatographic fractions from 
the ileal extract were assayed with both the C- and 
N-terminally directed antisera, a single peak of im- 
munoreactivity was detected co-eluting with syn- 
thetic neurotensin (fig.3). The elution position of 
neuromedin N is clearly distinguishable from that 
of neurotensin. This suggests that the immuno- 
reactivity co-eluting with neuromedin N was not a 
breakdown product of tissue neurotensin. One of 
the striking findings in this study is that a con- 
siderable amount of immunoreactive neuromedin 
N is found in the rat kidney, whereas no immuno- 
reactive neurotensin was detected with either 
neurotensin antisera. The absence of neurotensin 
in the rat kidney is in agreement with the finding 
of Godert and Emson [7] in the cat. However, as 
neurotensin-like receptors are found in the kidney 
(81, the exact nature of these receptors in relation 
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Fig.2. HPLC profiles of neuromedin N (NNLI) of 
pooled ileal extracts (upper) and pooled kidney extracts 
(lower). The Techsil Cl8 column (0.39 x 30 cm) was 
eluted with a gradient from 20 to 50% (0.5%/min) 
acetonitrile in distilled water containing 0.1% trifluoro- 
acetic acid. Fractions of 1 ml were collected, and ali- 
quots (0.1 ml) of each fraction were assayed for 
neuromedin N. The elution positions of neuromedin N 
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Fig.3. HPLC profiles of neurotensin (NTLI). The same 
chromatographic fractions of pooled ileal extracts as in 
fig.2 were measured for neurotensin with the C- 
terminally directed antiserum (upper) and N-terminally 
and neurotensin are indicated. directed antiserum (lower). 
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to neuromedin N requires elucidation. Checler et 
al. [9] have most recently reported that neuro- 
medin N binds to neurotensin receptors in the rat 
hypothalamus. Structurally related bioactive pep- 
tides may be derived from the same peptide precur- 
sor, a duplication of genetic material having 
occurred earlier in evolution. Post-translational 
processing and organ-specific differentiation of 
the peptide precursor may occur, allowing diver- 
sification of biological function. The question that 
neuromedin N and neurotensin may be derived 
from the same mRNA remains open but if so it is 
clear that post-translational enzymic processing 
must differ from tissue to tissue. 
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